Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SDCBP | O00560 | 2/20 | 0.33 |
| ▸ | SDC2 | P34741 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6536861 | 0.82 | LMNA (0.56) | HPGDMEN1FAAHMAPK1KMT2A | |
| SCHEMBL12448086 | 0.80 | HPGD (0.51) | HPGDMEN1FAAHMAPK1KMT2A | |
| SCHEMBL13241285 | 0.79 | HPGD (0.44) | HPGDMEN1FAAHMAPK1KMT2A | |
| SCHEMBL25083266 | 0.78 | HPGD (0.50) | HPGDMEN1FAAHMAPK1KMT2A | |
| SCHEMBL5909062 | 0.78 | MEN1 (0.62) | HPGDMEN1FAAHMAPK1KMT2A | |
| SCHEMBL17661831 | 0.77 | MAPK1 (0.44) | HPGDMEN1FAAHMAPK1KMT2A | |
| SCHEMBL21972899 | 0.77 | MEN1 (0.52) | HPGDMEN1FAAHMAPK1KMT2A | |
| SCHEMBL22916866 | 0.77 | FAAH (0.45) | HPGDFAAHKMT2AMAPTALDH1A1 | |
| SCHEMBL12132164 | 0.76 | CPB1 (0.45) | HPGDMEN1FAAHMAPK1KMT2A | |
| SCHEMBL18857492 | 0.75 | HPGD (0.47) | HPGDMEN1FAAHMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238439-A1 | HER3-BINDING ANTIBODY-DRUG CONJUGATE | Hummingbird Bioscience Pte. Ltd. (SG) | 2024-07-18 | — | — | US | disclosed |
| WO-2021216572-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-10-28 | — | — | WO | disclosed |
| US-9988420-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238439-A1 | HER3-BINDING ANTIBODY-DRUG CONJUGATE | ERBB3, EGFR, ERBB2 | HPGD 4682/4885MEN1 557/4885FAAH 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.